Hepatitis B Therapy
Phase III hepatitis B trial for Zadaxin shows positive results
Published in Hepatitis Weekly, April 8th, 2002
Preliminary data on approximately one-third of the 319 patients indicate that, after 6 months of therapy and 12 months of follow up, 24% demonstrated a successful interruption of viral replication, as measured by sustained seroconversion of hepatitis B e-antigen (loss of HBeAg and the development of antibody to HBeAg).
By comparison, published data on lamivudine, the drug most widely used for treatment of hepatitis B worldwide, indicate that lamivudine is capable of inducing sustained...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2002-04-08)
More Articles from Hepatitis Weekly
- Transfusion Medicine
Hepatitis reactivation likely with autologous blood cell transplant - Vaccine Coverage
Combined vaccines effective, may mean better vaccine program adherence - Fatty Liver Disease
Genetic mutation may be marker for steatohepatitis, insulin resistance - Hepatocellular Carcinoma
For small liver tumors, surgical removal preferable for initial treatment - Diagnostics
LabCorp introduces new suite of molecular assays for hepatitis - Hepatitis B Therapy
Zadaxin with interferon has superior sustained response rates, data suggest - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
